Public Board of Directors papers 260123

CH noted that risk 8.2 – net carbon zero, this has now been reviewed by the Audit Committee. This risk refers to our in-year achievement of the objectives in our plan. 39/22 Key Reports a Trust report RS noted the reference to our top operational risks in the report. The report describes details of our performance. Financial performance is on plan for break even. The ICB have escalated a deteriorating financial problem for the system, this will be further discussed. Operational performance remains strong, we still have some late referrals for 62 days. RS highlighted the notification from the Covid-19 public enquiry who have contacted every Trust to tell us that they will send us a questionnaire as part of the enquiry. Sustainability – we have won a National NT award for best social responsibility for our green crusade led by the sustainability team and Angela Hayes. The work has been done with community partners to progress our sustainability plans. RS noted the item about feedback on the MCRC review, this was from international partners and the feedback was excellent, particularly about organisational arrangements and some specific research areas (Radiotherapy / Lung etc). CO noted that we had our CQC Inspection last week and thanked everyone for their input into the process and for the tremendous amount of work undertaken. The inspection process has not yet concluded. GP asked about the industrial action and how robust our planning has been. CO noted that there is an item to follow that covers this in more detail. b Integrated performance, quality & finance report BD outlined the September performance. There have been no SI incidents, never events or major incidents. 11 moderate incidents that are going through review and 12 falls that is higher than normal. These are being reviewed in detail. There were 2 cases of C.difficile with no lapses in care, 5 cases of E-Coli post 48 hours and 15 Covid nosocomial infections. We had 13 new complaints in month with 37 PALS contacts received, LOS at 6.34 and 4 cancelled operations, 2 relating to radiology. 62 days improved compared to the previous month, we are still getting a lot of late referrals. 5 corporate risks at 15+; 1 at 16 and 4 at 15. In terms of things to note for access, 24-day performance is key and this was 85.5%. 31-day performance at 96.5% which is the area for the majority of Activity is overall on plan, surgical operations are above plan and day cases slightly behind. New attendances are slightly behind – validation is taking place as chemotherapy /radiotherapy first treatments are on plan. PDR compliance has dropped slightly to 81.8%, the clinical divisions are the main focus. Essential training overall is at 85.9%, additional sessions are being patients. There are 40 104+ day patients. Referrals are within the predicted range.

5